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ABSTRACT Antimalarial drug resistance in the Plasmodium falciparum parasite
poses a constant challenge for drug development. To mitigate this risk, new antima-
larial medicines should be developed as ﬁxed-dose combinations. Assessing the
pharmacodynamic interactions of potential antimalarial drug combination partners
during early phases of development is essential in developing the targeted parasito-
logical and clinical proﬁle of the ﬁnal drug product. Here, we have studied the com-
bination of M5717, a P. falciparum translation elongation factor 2 inhibitor, and py-
ronaridine, an inhibitor of hemozoin formation. Our test cascade consisted of in vitro
isobolograms as well as in vivo studies in the P. falciparum severe combined immu-
nodeﬁcient (SCID) mouse model. We also analyzed pharmacokinetic and pharmaco-
dynamic parameters, including genomic sequencing of recrudescent parasites. We
observed no pharmacokinetic interactions with the combination of M5717 and pyro-
naridine. M5717 did not negatively impact the rate of kill of the faster-acting pyro-
naridine, and the latter was able to suppress the selection of M5717-resistant mu-
tants, as well as signiﬁcantly delay the recrudescence of parasites both with
suboptimal and optimal dosing regimens.
KEYWORDS M5717, Plasmodium falciparum, SCID mouse, drug combination,
isobologram, malaria, pyronaridine, resistant mutant
Antimalarial drug resistance in Plasmodium falciparum has led to the demise ofmultiple ﬁrst-line treatments, including chloroquine, proguanil, pyrimethamine,
sulfadoxine-pyrimethamine, meﬂoquine, and more recently the artemisinin-based com-
bination therapy dihydroartemisinin-piperaquine, which was recently reported to pro-
duce only a 50% adequate clinical and parasitological response in sites across the
Greater Mekong subregion (1–3).
To mitigate the risk of resistance, new antimalarial drugs should be developed as
ﬁxed-dose combinations. The rationale for combination therapy is that any parasite
resistant to one component should be eliminated by the other, provided that both
have distinct modes of action. This strategy is expected to signiﬁcantly reduce the
emergence of resistance (4). However, other factors that inﬂuence the emergence of
drug resistance must be taken into account, including drug exposure, drug half-life,
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effects of the drug on other parasite life-cycle stages such as gametocytogenesis and
gametocyte viability, clinical parasite reduction ratio, and drug dosage (5, 6).
Recently, a quinoline-4-carboxamide antiplasmodial series was optimized to deliver
lead molecules with low nanomolar in vitro potency and excellent oral efﬁcacy in the
Plasmodium bergheimalaria mouse model with ED90 values below 1mg/kg when dosed
orally for 4 days (7, 8). The favorable efﬁcacy, potency, selectivity, drug metabolism and
pharmacokinetic (DMPK) properties, coupled with a novel mechanism of action, namely
inhibition of P. falciparum translation elongation factor 2 (PfeEF2), led to the progres-
sion of M5717 (also known as DDD107498) from preclinical to clinical development (Fig.
1) (7, 8). The mean half-life (t1/2) ranged from 155 h to 193 h across doses in human
volunteers. From a parasitological standpoint, M5717 is potent across the parasite life
cycle. Due to its mode of action, the anti-parasitological activity is characterized by a
rapid arrest of parasite growth with a delayed clearance of parasites from circulation,
while also acting on liver stages and gametocytes. This multistage activity provides
additional beneﬁts for treatment, such as prophylaxis or transmission-blocking poten-
tial (9). Not surprisingly, at clinically relevant parasite inoculum levels, M5717-resistant
parasites can be selected in vitro and lead to various degrees of susceptibility, high-
lighting the need for a well-selected partner drug during the combination phases (7).
With this in mind, we selected pyronaridine (10–15), a benzonaphthyridine deriva-
tive discovered in China in the late 1970s, for partnering with M5717. Pyronaridine
fulﬁlled three criteria that seemed to provide reasonable prerequisites for the combi-
nation strategy (Fig. 1): (i) matching half-lives to avoid periods where only one drug
achieves therapeutic levels, where pyronaridine is a long-lasting drug with a t1/2 of 241
h at 400 mg in healthy volunteers (16); (ii) complementary modes of action in regard to
the rate of killing, where pyronaridine is a fast-acting (chloroquine-like) drug that has
the demonstrated ability to inhibit -hematin formation in vitro (17, 18); and (iii) a lack
of resistance reported to date in P. falciparum (19).
Here, we describe the pharmacokinetic and pharmacodynamic properties of the
combination of M5717 and pyronaridine, both in vitro through asexual blood-stage P.
falciparum parasites as well as in vivo by means of the well-established P. falciparum
SCID mouse model (20). The objective of the studies was to evaluate and describe the
parasitological behavior and pharmacokinetic parameters of the two compounds when
used in combination.
RESULTS
In vitro drug interactions. We observed no interaction between M5717 and
pyronaridine with our in vitro isobologram experiments with three different assay
durations (Table 1; see Materials and Methods). Experimental half maximal effective
concentration (EC50) values (M5717, 0.3 nM; pyronaridine, 3.5 nM; atovaquone, 0.4 nM;
proguanil, 5.5 M; [3H]hypoxanthine incorporation, 72 h, NF54 strain) of P. falciparum
were in close agreement with the literature (21), and we observed the sum of the
fractional 50% inhibitory concentration (FIC50) values in the range of 1.3 to 1.7 from
three independent experiments for this combination conducted for 48 and 72 h. These
results suggested that the interactions between M5717 and pyronaridine were not
detrimental, but rather were additive under these test conditions. Control experiments
FIG 1 Chemical structures of M5717 and pyronaridine.
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with the previously described synergistic drug combination of atovaquone proguanil
showed the expected level of synergy, with FIC50 values in the range of 0.2 to 0.4
across 48 h and 72 h assays (Table 1) (22).
In vivo combination. We observed no detrimental pharmacodynamic and pharma-
cokinetic interactions between M5717 and pyronaridine with our in vivo combination
experiments (Table 2; see Materials and Methods).
When administered alone, M5717 displayed a half-life (t1/2) of 37 h (Fig. S1 in the
supplemental material). M5717 showed a dose proportionality in exposure (AUC0-inf) at
3, 6, 12, and 30 mg/kg, with a parasite clearance time in line with previously described
experiments, i.e., we observed a biphasic clearance of parasitemia with a breakpoint at
around 48 h between both phases. The ﬁrst phase was characterized by a low parasite
reduction ratio (PRR) and a long half-life of circulating parasites, while the second phase
showed a rapid decline in parasitemia with higher PRR and a shorter half-life (entries 1
to 4) (7). Parasite recrudescence could be extended until day 24 with a plateau between
12 and 30 mg/kg. Sequencing of parasites recrudescing from the 30 mg/kg dose group
indicated mutation of amino acids 182 and 138 in the eEF2 site (Table S4).
Pyronaridine dosed at 6, 12, and 36 mg/kg showed a good dose linearity and led to
a rapid decline in parasitemia in 2 days (entries 5 to 7). With a dose of 36 mg/kg, there
was no parasite recrudescence as of day 60, when the experiment was concluded. The
t1/2 of pyronaridine was estimated at 74 h (Fig. S1).
In combination with pyronaridine, the pharmacokinetics of M5717 (Cmax, AUC0-inf,
and t1/2) were unchanged compared to M5717 administered alone (entries 8 to 11). No
change was observed in pyronaridine pharmacokinetics in the combination versus the
single-agent treatments. Also, there was no relevant effect of M5717 on the rate of kill
of pyronaridine at higher doses such as 12 and 36 mg/kg (entries 10 and 11).
TABLE 1 In vitro drug combination assays for M5717pyronaridine and atovaquoneproguanil in the NF54 straina,b
Drug partners
FIC50
at 48 h
FIC50
at 72 h Interaction at 72 h
Combination
ratio Drug partners
FIC50
at 48 h
FIC50
at 72 h
Interaction
at 72 h
M5717  PYRO 1.7  0.12 1.4  0.12 Nondetrimental interaction 1  3 ATO  PRO 0.4  0.04 0.3  0.08 Synergistic
M5717  PYRO 1.5  0.38 1.4  0.26 Nondetrimental interaction 1  1 ATO  PRO 0.3  0.06 0.3  0.05 Synergistic
M5717  PYRO 1.3  0.17 1.4  017 Nondetrimental interaction 3  1 ATO  PRO 0.3  0.03 0.2  0.05 Synergistic
aATO, atovaquone; PRO, proguanil; PYRO, pyronaridine.
bFIC50 (fractional inhibitory concentrations) indicate the following: synergism at FIC50 0.5; antagonism at FIC50 2.0; nondetrimental interactions when
0.5 ¥FIC50 2.0. The values show the mean of 3 independent assays for NF54.
TABLE 2 Pharmacodynamic (PD) and pharmacokinetic (PK) properties of M5717, pyronaridine, and M5717 pyronaridine combination in
vivo against P. falciparum Pf3D70087/N9 administered as a single oral dose
Entry
M5717 exposure Pyronaridine exposure Parasitemiab
Dose (mg/kg) AUC0-infa (ng · h/ml) Dose (mg/kg) AUC0-infa (ng · h/ml) Day 3 Day 4 Day 5 Day 6 Mean DoRc n
A 0 Not measured 0 Not measured 1.48 2.53 7.00 9.00 3 4
B 0 Not measured 0 Not measured 0.85 1.91 3.34 6.16 3 4
1 3 1,570  139 0 Not measured 1.2 0.65 0.49 0.19 6 2
2 6 3,390  479 0 Not measured 1.26 1.4 1.03 0.46 17 2
3 12 6,160  454 0 Not measured 0.81 0.58 0.53 0.11 24 4
4 30 16,900  199 0 Not measured 0.89 0.73 0.54 0.21 24 2
5 0 Not measured 6 6,560  381 0.89 0.09 0.01 0.00d 24 to 35 2
6 0 Not measured 12 14,500  1,060 1.51 0.13 0.00d 0.00d 35 2
7 0 Not measured 36 55,600  2,080 1.61 0.12 0.00d 0.00d 60e 2
8 3 1,360  94 6 8,500  661 1.25 0.61 0.03 0.00d 35 2
9 12 6,400  257 6 8,490  2,260 0.83 0.34 0.03 0.04 45 3
10 12 6,650  645 12 12,100  1,820 0.83 0.21 0.01 0.00d 44 3
11 6 2,980118 36 58,200  193 1.29 0.24 0.03 0.00d 60e 2
aThe AUCs are mean values  SD with n 2.
bMean % parasitemia as assessed by microscopy.
cDoR, day of recrudescence, uncorrected (days postinfection; treatment was made on day 3).
dReached the lower limit of quantiﬁcation (LLQ 0.01% parasitemia).
eExperiment ended at day 60 with parasitemia 0.01%.
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To further explore this combination and to bring more relevance, we decided to
dose three groups of ﬁve mice. All groups were treated with the same suboptimal dose
of M5717, i.e., 12 mg/kg single oral dose. We then added pyronaridine in two groups
with 6 mg/kg and 12 mg/kg single oral doses, respectively. As previously described, a
single oral dose of 12 mg/kg of M5717 displayed a delayed parasite clearance (Fig. 2A),
where the lowest limit of quantiﬁcation (LLQ) was reached after day 7 (i.e., day 8)
postinfection (7). When combining M5717 with 6 mg/kg of pyronaridine, a similar
parasite clearance time was observed, suggesting that the latter dose was suboptimal.
However, on increasing the dose of pyronaridine to 12 mg/kg, the parasite clearance
time was substantially increased and reached the LLQ at day 6 (Fig. 2A).
With a single 12 mg/kg oral dose of M5717, all mice displayed parasite recrudes-
cence above the LLQ (0.01%) around the third week postinfection (Fig. 2B). Mice with
early recrudescence (D17, D18, and D19) were not susceptible to retreatment with the
same dosing regimen, as opposed to mice with later-recrudescing parasites (D23 and
D24), which responded partially to retreatment.
With the same dose of M5717 (12 mg/kg), in combination with a suboptimal dose
of pyronaridine at 6 mg/kg, the recrudescence pattern was partially affected (Fig. 2C).
Mice had parasites reemerging between days 21 and 33 with a full response (i.e., similar
rate of kill as in the initial treatment), from which two recrudesced again 28 to 36 days
after retreatment, suggesting that the overall dose was suboptimal. When the dose of
pyronaridine was increased to a more optimal dose of 12 mg/kg, the recrudescence
pattern was altered again, with three mice showing no recrudescence at all by day 80
(Fig. 2D). The two mice with late recrudescence at around 7 weeks postinfection
responded fully to the same retreatment.
FIG 2 Pharmacodynamics upon single oral treatment of M5717 and pyronaridine (Pyro) as single agents or in combination against P.
falciparum Pf3D70087/N9. (A) Parasite reduction rates from day 3 to day 7 compared to control (mean values, n 5). (B) Five mice (M1
, M2 Œ, M3, M4 ●, M5 	) were treated with a 12 mg/kg single oral dose of M5717 at day 3 postinfection (red arrow). (C) Five mice
(M1’ , M2’ Œ, M3’ , M4’ ●, M5’ 	) were treated with a single oral dose of 12 mg/kg M5717 and 6 mg/kg pyronaridine at day 3
postinfection (red arrow). (D) Five mice (M1” , M2” Œ, M3”, M4” ●, M5” 	) were treated with a 12 mg/kg single oral dose of M5717
and pyronaridine at day 3 postinfection (red arrow). Parasitemia was measured by microscopy. Gray areas correspond to retreatments
with the same initial dosing regimen at day 3 postinfection.
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In vivo selection of mutants. We observed that monotherapy with M5717 in the
murine P. falciparum SCID model can lead to selection of mutant parasites, and the
addition of a suboptimal dose of pyronaridine during a combination treatment can
clear M5717-related resistance (Fig. 3; see Materials and Methods).
In the 12 mg/kg M5717 treatment arm, parasites reemerged in all mice. The median
time to recrudescence of parasites in mice (M1, M2, M3, n 3) showing no response to
retreatment was 18 days. Sequencing indicated the mutation Y186N (Table S3) in the P.
falciparum eEF2 site that has conferred high-grade resistance (3,000-fold shift of half
maximal inhibitory concentration [IC50]) in prior in vitro studies (7). Mice exhibiting later
recrudescence (M4 and M5, n 2) showed a median recrudescence at 23.5 days and
partially responded to retreatment. Sequencing of these mice showed the mutation
T753N in the P. falciparum eEF2 site. Nearby mutations P754A, P754S, and L755F had
IC50 fold shifts of 135-, 200-, and 660-fold, respectively, in prior in vitro studies, with the
position 754 mutations corresponding to medium-grade resistance (7). Although the
difference between early and late recrudescence groups was not signiﬁcant (P  0.06),
the comparison was based on very small sample sizes (n 3 and n 2), so the P value
of borderline signiﬁcance should not be interpreted as no difference in recrudescence
time. Overall, resistance evolved in 5/5 mice in the 12 mg/kg M5717 arm, with a median
time to recrudescence of 19 days (Table S5).
When adding a suboptimal dose of pyronaridine of 6 mg/kg to the 12 mg/kg of
M5717 (n 5), the median time to recrudescence was signiﬁcantly shifted to 26 days
(P  0.0127). All parasites were sequenced and were found to be wild type, conﬁrming
that (i) combination with pyronaridine effectively suppressed the emergence of M5717-
resistant parasites and (ii) the combined doses were subtherapeutic. Finally, when
increasing the dose of pyronaridine to 12 mg/kg with 12 mg/kg of M5717 (n 5), 3
mice were deemed cured, i.e., no recrudescence at day 80, while 2 mice (M1” and M2”)
showed a median recrudescence on day 50 with wild-type parasites, as determined by
sequencing. This increase in dose of pyronaridine signiﬁcantly shifted the outcome
compared to a suboptimal dose of pyronaridine (P  0.0018).
DISCUSSION
The pressing need for new antimalarial combinations is mandated by the current
decline in efﬁcacy in artemisinin-based combination therapies in Southeast Asia, which
has historically served as the bellwether for resistance emerging or spreading globally.
Here, we report PK/PD studies on combinations of two potent antimalarials, M5717 and
pyronaridine. Our study employed in vitro cultures of asexual blood-stage P. falciparum
parasites and in vivo trials using the P. falciparum SCID mouse model. Overall the
parasitological behavior was additive, and no pharmacokinetic interactions were ob-
served when the two substances were given in combination.
We hypothesized that M5717, the slower-acting partner that inhibits the parasite
eukaryotic elongation factor PfeEF2, and pyronaridine, the faster-acting partner that
inhibits the formation of hemozoin, could be an interesting pairing of antimalarials
given their potential matching pharmacokinetic proﬁles (e.g., similar t1/2) and comple-
FIG 3 Time to recrudescence (0.01% parasitemia) and parasite mutation proﬁles as a function of single
oral treatments with 12 mg/kg single oral doses of M5717 (●), 12 mg/kg M5717 and 6 mg/kg pyronari-
dine (Œ), and 12 mg/kg single oral dose of M5717 and pyronaridine () at day 3 postinfection.
Parasitemia was measured by microscopy. Red icons correspond to M5717-mutant parasites with a high
grade of resistance. Orange icons correspond to M5717-mutant parasites with a medium grade of
resistance. Green icons correspond to wild-type parasites. *, P  0.05; **, P  0.01; NS, not signiﬁcant.
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mentary pharmacodynamic characteristics. Pyronaridine was recently approved by the
European Medicines Agency (EMA) (Article 58) in combination with artesunate under
the brand name Pyramax by Shin-Poong Pharmaceutical, and several reports have
studied the in vitro combination of pyronaridine and artesunate (19, 23, 24). This
prompted a ﬁrst in vitro assessment entailing isobologram analyses after various
durations of exposure. Results were consistent with a mostly additive effect (Table 1).
Given their additive effect and long t1/2 proﬁles in mice, namely, 37 h for M5717 and
74 h for pyronaridine, we proceeded with single oral dosing in the P. falciparum SCID
mice model. For both compounds we measured pharmacokinetic (AUC0-inf) and phar-
macodynamic (% parasitemia, day of recrudescence, sequencing) parameters. No phar-
macokinetic interactions were observed between the two substances in the peripheral
blood (Table 2). Overall, the two compounds showed additive parasitological proper-
ties, i.e., the rate of kill of pyronaridine seemed unaffected at therapeutic doses, and a
delay in recrudescence was observed in combined treatment compared to mono-
therapy. Alone, pyronaridine was able to linearly extend the recrudescence time with
doses of 6, 12, or 36 mg/kg. Conversely, a plateau to recrudescence was reached from
12mg/kg to 30 mg/kg with M5717.
DNA sequencing showed that M5717-resistant parasites had been selected, i.e.,
mutation occurred in the eEF2 locus that conferred a high degree of resistance. As it has
been shown for atovaquone in the P. berghei mouse model, in-host selection of
mutant parasites is possible and can be dose dependent, i.e., high doses yield
highly resistant mutant selection whereas low doses can show selection of low-
grade resistance (25, 26).
To further investigate the effects of the combination on parasite recrudescence and
M5717-resistant mutant selection, we chose a suboptimal dose of M5717 ﬁxed at
12 mg/kg in all of the three treatment arms (n 5 for each) followed by an increasing
dose of the partner agent, pyronaridine at 6 or 12 mg/kg (Fig. 2). Monotherapy with
M5717 at 12 mg/kg led to median recrudescence at day 20 with two subpopulations of
mutants. By sequencing the monotherapy arm parasites, we showed that mutation in
the eEF2 locus could be translated into no or partial response to retreatment with
M5717 (Fig. 2B). Next, by gradually increasing the dose of the partner drug pyronaridine
to a therapeutically relevant level, the parasite recrudescence pattern was favorably
altered. We found that the addition of a suboptimal dose of pyronaridine totally
suppressed the emergence of mutant parasites and also postponed the time to
recrudescence signiﬁcantly compared to M5717 alone (P 0.05). In addition, increasing
the dose of pyronaridine to 12 mg/kg along with a 12 mg/kg dose of M5717 gave a cure
rate of 60% at day 80 and signiﬁcantly postponed the day of recrudescence for the
other mice (P  0.001). These ﬁndings indicate that M5717 should not be exposed to
parasites as a monotherapy and provide evidence that the constant presence of a
partner drug in a matching pharmacokinetic and pharmacodynamic fashion is recom-
mended, assuming that the observations made in mice are translatable to humans.
The results described are the ﬁrst report suggesting that M5717, a Plasmodium eEF2
inhibitor, and pyronaridine, a hemozoin formation inhibitor, could be an effective,
long-lasting antimalarial combination with complementary pharmacodynamic proﬁles.
The combination maintains fast clearance of blood-stage parasites while adding exo-
erythrocytic activity, consequently providing additional beneﬁts for treatment, such as
prophylaxis or transmission-blocking potential. Our isobologram data, combined with
drug combination experiments in the P. falciparum SCID mouse model coupled with
pharmacokinetic sampling and parasite sequencing, highlights the promise of this
potential new antimalarial combination.
Overall, molecules with a high propensity for generating resistance should be
combined with a partner drug having, at a minimum, a matching anti-parasitic expo-
sure with no or low propensity to generating resistance at relevant parasite inocula. If,
in addition, these molecules have activity on exoerythrocytic stages (liver and gametes),
then targeting populations with low parasitemia for prevention and prophylaxis rather
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than cure could leverage their full potential in view of supporting the malaria-
elimination agenda.
MATERIALS AND METHODS
In vitro isobolograms. IC50 and drug interaction studies were performed as previously described (27,
28). Drug solutions were diluted with hypoxanthine-free culture medium to initial concentrations of 10
times the predetermined IC50 (named S10	 IC50). The S10	 IC50 solutions for each compound were
combined in ratios of 1 3, 1 1, or 3 1, and each drug was also tested alone (Table 1). Aliquots of
100 l of single and combination drug solutions were then introduced into 96-well plates to give
duplicate rows and drugs were diluted 2-fold across a range of 10 concentrations. Equal volumes of
parasite culture with a parasitemia of 0.3% in a 2.5% erythrocyte suspension were added and the test
plates were incubated for 24 h, 48 h, or 72 h. Parasite growth was measured by the incorporation of
radiolabeled [3H]hypoxanthine (0.25 Ci in a volume of 50 l hypoxanthine-free culture medium) added
8 h (for 24 h assay duration) or 24 h (48 h and 72 h assay duration) prior to the termination of the test.
Cultures were harvested onto glass ﬁber ﬁlters, washed, and the radioactivity was counted using a
MicroBetaplate liquid scintillation counter and recorded as counts per minute (cpm) per well. Results are
expressed as a percentage of the untreated controls (see the supplemental material for more details).
Isobolograms were constructed by plotting the fractional inhibitory concentrations producing half-
maximal growth (FIC50s) of drug A against the FIC50s of drug B for each of the three drug ratios. A
concave curve indicated synergy, a straight line indicated additivity, and a convex curve indicated
antagonism (see supplemental material). To obtain numeric values for the interaction, results were
expressed as the sum of the FIC50A and FIC50B. Sum FIC50 values characterize the interactions as follows:
synergism when the FIC50 is 0.5; antagonism when the FIC50 is 2.0; no interaction when
0.5 ¥FIC50 2.0 (29).
In vivo SCID mouse model. Compound efﬁcacy was assessed in the murine P. falciparum SCID model
essentially as described by Jimenez-Díaz et al. (20). Brieﬂy, alone or in combination, M5717 (succinate salt by
Merck KGaA [MSC2576186-B4]) and pyronaridine (tetraphosphate salt, Sigma-Aldrich [P0049]) were formu-
lated in 7% Tween80, 3% ethanol and administered to a cohort of age-matched female immunodeﬁcient
NOD-scid IL-2Rnullmice (Jackson Laboratory, Bar Harbor, ME). These mice had been previously engrafted with
human erythrocytes (generously provided by the blood bank in Zürich, Switzerland). Prior to compound
treatment, mice were intravenously infected with 2	 107 P. falciparum Pf3D70087/N9 -
infected erythrocytes (day 0) (30). On day 3 after infection, mice, in groups of 2 to 5, were randomly allocated
to treatments that were administered with a single oral gavage at 10ml/kg (Table 2 and Fig. 2). Parasitemia
was measured by microscopy. Chimerism was monitored by ﬂow cytometry using an anti-murine erythrocyte
TER119 monoclonal antibody (Pharmingen, San Diego, CA) and SYTO-16 and then analyzed by ﬂow cytom-
etry in serial blood samples (2l) collected every 2 to 3 days until the completion of the experiment (Table
2, day 60 and Fig. 2, day 80). Parasite recrudescence was detected by microscopy. Once parasitemia exceeded
0.5%, then 100 to 500 l of blood was collected and stored at –80°C for subsequent sequence analysis.
Animals received a second treatment with the same dose and if applicable the same combination of
compounds as previously administered in that dose group (Fig. 2). Efﬁcacy was again monitored by
microscopy. If recrudescence occurred again then new blood samples were stored at –80°C.
In vivo studies conducted at the Swiss TPH, Basel, were approved by the veterinary authorities of the
Canton Basel-Stadt (permit no. 2303) based on Swiss cantonal (Verordnung Veterinäramt Basel-Stadt)
and national regulations (the Swiss animal protection law, Tierschutzgesetz).
Pharmacokinetic analysis. The test compounds’ concentrations in blood were assessed in order to
determine pharmacokinetic parameters in mice from the efﬁcacy study. Peripheral blood samples (20 l)
were sampled at different time points (1, 2, 4, 6, 24, 48, 72, 96, 168, and 216 h post treatment), mixed
with 20 l of H2O Milli Q and immediately frozen on dry ice. Samples were stored at –80°C until analysis.
Blood from control mice was used for bioanalysis calibration and QC purposes. For liquid chromatog-
raphy with tandem mass spectrometry (LC-MS/MS) analysis, the frozen samples were thawed and treated
with two volumes equivalent of acetonitrile containing the internal standard. After centrifugation, one volume
equivalent of supernatant was diluted with one volume equivalent of water containing heptaﬂuorobutyric
acid (HFBA). The extracts were analyzed by LC-MS/MS (quantiﬁcation by HESI ionization in positive ion mode)
performed at Swiss BioQuant AG (Switzerland). A noncompartmental analysis was performed to determine
pharmacokinetic parameters using the Phoenix WinNonlin program (version 6.3).
Sequencing P. falciparum blood samples for eEF2 mutations. Blood samples collected from mice
with recrudescent infections were lysed in 0.1% saponin and washed twice with 1	 phosphate-buffered
saline (PBS), with repeat rounds as necessary. DNA was then extracted using the DNeasy blood and tissue
kit (Qiagen). The 2.7 kb PfeEF2 gene was PCR-ampliﬁed using ﬂanking primers (Table S2). The PCR
conditions for the initial ampliﬁcation were: 95°C for 3 min, 45 rounds of 98°C for 20 s, 55°C for 30 s, and
68°C for 2.5 min, with a ﬁnal extension of 3 min at 68°C. Agarose gel (1%) electrophoresis was used to
conﬁrm the PCR product size. Sanger sequencing was carried out by Genewiz Inc. In addition to the
ampliﬁcation primers, nine additional sequencing primers were used to fully sequence the PfeEF2 gene
(Table S2). All the sequences were aligned to the wild-type eEF2 3D7 sequence and analyzed on
DNASTAR SeqMan Pro 15 software. Electropherograms were visually inspected to identify mixed se-
quences indicating multiple subpopulations.
Statistical analysis. Time-to-recrudescence data were analyzed using the Kaplan-Meier method.
Log-rank test was performed for two-group comparisons. Kaplan-Meier curves and log-rank test P values,
as well as median estimates for time to recrudescence, are presented (SAS, Version 9.4. Cary, NC: SAS
Institute Inc.; 2014).
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